BRKR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BRKR is not a strong buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock has improved on better-than-expected Q1 results and firmer bookings, but the latest quarter still showed weaker organic revenue, sharply lower EPS, and margin pressure. Technically it is short-term overbought after the recent jump, and Wall Street remains mostly Neutral/Hold despite some higher targets. My direct view: hold off on buying now and wait for a better entry.
The short-term trend is constructive but stretched. MACD histogram is positive and expanding, which supports near-term momentum. However, RSI_6 at 80.769 signals overbought conditions, making the current level less attractive for an immediate entry. Price closed at 42.48, just below R1 at 42.616 and near resistance, with pivot support at 38.61. Moving averages are converging, suggesting the bigger trend is not yet firmly established. Overall: bullish momentum in the short run, but the stock is extended and not an ideal beginner long-term entry today.
["Q1 EPS of $0.31 beat estimates by $0.08", "Revenue of $823.4 million grew 2.7% YoY", "Bookings showed high-single-digit organic growth with book-to-bill above 1.0 for the third straight quarter", "Management reaffirmed FY2026 revenue guidance of $3.57B to $3.60B", "Company secured about $80 million in multi-year orders in Q1", "Superconductor orders reached about $600 million over the last five months", "Analysts at TD Cowen and Citi raised price targets after Q1 results", "Barclays remains Overweight and raised its target to $53"]
["Q1 organic revenue declined 4.4%", "GAAP EPS fell sharply to $0.02 from $0.11 year over year", "Net income dropped 79.89% YoY", "Gross margin declined to 46.13%", "TD Cowen and UBS still rate the stock Hold/Neutral", "Price is near technical resistance after a sharp move", "RSI is overbought, limiting near-term upside appeal"]
Latest quarter: Q1 2026. Revenue increased 2.75% YoY to $823.4 million, which was a solid top-line beat versus expectations. Bookings were a bright spot, with high-single-digit organic growth and book-to-bill above 1.0. However, bottom-line performance weakened materially: net income fell to $3.5 million, EPS dropped to $0.02, and gross margin fell to 46.13%. The quarter shows better demand momentum, but profitability remains under pressure.
Analyst sentiment is mixed to cautious. Recent action included several price target raises after Q1, with TD Cowen to $45, UBS to $45, Citi to $44, and Barclays to $53. Despite that, TD Cowen and UBS remain Hold/Neutral, Citi is Neutral, and only Barclays is clearly bullish with Overweight. Earlier in the year, several firms cut targets after weak Q4 results. Wall Street pros see improving bookings and firmer end markets as positives, but they still worry about margins, organic growth, and the pace of the recovery. Overall, the pros view is cautious-to-moderately positive rather than outright bullish.
